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Introduction  
 
Non-cirrhotic portal hypertension (NCPH) is often a diagnostic challenge due to signs and symptoms 
of portal hypertension that overlap with cirrhosis. The etiology of NCPH is broadly classified as 
prehepatic, hepatic (pre-sinusoidal and sinusoidal) and post-hepatic.1 Some common etiologies of 
NCPH encountered in clinical practice include portal vein thrombosis (prehepatic) and nodular 
regenerative hyperplasia (NRH) (hepatic). Liver histology, although considered gold standard to 
exclude cirrhosis in individuals with suspected NCPH, is often limited by subtle histologic features or 
inadequate sampling. Liver stiffness measurements (LSM) by vibration-controlled transient 
elastography (VCTE) may provide clinically important information to distinguish NCPH from cirrhosis 
by revealing normal LSM in prehepatic and presinusoidal NCPH.  
 
Clinical Observation 
 
Forty-three patients with a diagnosis of NCPH based on clinical, radiologic, histologic and portal 
pressure measurements, also underwent VCTE using Fibroscan 502 Touch for LSM. Cirrhosis was 
excluded by histology in 88% (38/43) of the cohort. The common etiologies of NCPH in the cohort 
were drug-induced NRH (51%) and portal vein thrombosis (30%). Esophageal and/or gastric varices 
were present in 74% of the cohort. In patients with NCPH, LSM correlated significantly with wedge 
hepatic vein pressure (r=0.48, p-value = 0.006) and HVPG (r=0.6, p-value = <0.001). Table 1 shows 
selected clinical and laboratory characteristics and portal pressure measurement. The proportion of 
patients with abnormal LSM indicative of compensated advanced chronic liver disease (>10kPa) as 
defined by Baveno VI was lowest at 31% in PVT as compared to 50% and 75% in NRH and 
miscellaneous categories of NCPH respectively (Figure 1).  Among the 13 cases with PVT, 11 
underwent portal pressure measurements; of these 5 had abnormal LSM (45%). In those with 
abnormal LSM, the free hepatic vein pressure was significantly higher 11 ± 3 vs. 6 ± 4 mm Hg (p-
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value = 0.033). Otherwise, right atrial pressure, wedge hepatic vein pressure and hepatic vein 
pressure gradient were not different between PVT patients with normal and abnormal LSM. The LSM 
in the NRH group ranged from 4.4 to 22.0 kPa with a good correlation with HVPG (r=0.52, p-value = 
0.047).  
Discussion 
Our assumption that LSM is normal in all patients with PVT was not observed in the current 
study as abnormal LSM was present in up to one-third of patients.  The abnormal LSM despite lack of 
fibrosis in the PVT group is likely due to its increase from an elevated FHVP.  The wide variation of 
LSM in NRH group may reflect the severity of NRH. Our findings are similar to one other study that 
reported a wide range of LSM   discouraging its role in diagnosing patients with NCPH.2 It has been 
suggested that in NRH, the pre-sinusoidal portal hypertension is related to obliterative portal 
venopathy while the sinusoidal portal hypertension is related to sinusoidal obstruction due to 
compression by regenerative nodules.3 In the current study, we found a good correlation between 
LSM and HVPG and likely indicative of the severity of NRH and underlying portal HTN. It is therefore 
conceivable that early in the course of NRH, the HVPG may be low primarily due to pre-sinusoidal 
portal hypertension.4  It is also possible that the variation in LSM in NRH is reflective of the 
predominant mechanism of injury (i.e., low LSM in pre-sinusoidal vs. high LSM in sinusoidal portal 
hypertension).4 Evaluating the use of VCTE in the diagnostic workup  of NCPH is a challenging topic 
to approach due to rarity and heterogeneity of the etiology due to varied chronicity, severity, and 
etiologies. From a cohort of cirrhotic patients that underwent upper endoscopy and VCTE, we 
identified control patients after matching for presence of esophageal varices (Supplementary Table 
1).  As anticipated the LSM values in the cirrhosis cohort were statistically significantly higher (26.6 ± 
18.4 vs. 13.2 ± 11.5 kPa, P- value = <0.001). Some limitations of the current study are the sample size 
and lack of single operator for the measurement of LSM and portal pressures. In summary, although 
intuitively appealing, the use of VCTE as a diagnostic tool to differentiate liver disorders associated 
with NCPH from cirrhosis and PVT from other causes of NCPH is fraught with complexities and LSM 
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must be interpreted with caution in patients with NCPH. 
Table 1. Select demographic, blood test parameters, liver histology, portal pressure measurements and 
liver stiffness measurement in the study cohort. All values are reported as mean ± SD unless otherwise 
reported.  
RA: right atrium; FHVP: free hepatic vein pressure; WHVP: wedge hepatic vein pressure; HVPG: Hepatic vein 
pressure gradient; LSM: liver stiffness measurement. Etiologies in “Miscellaneous” category included 
sarcoidosis, Budd-Chiari, acute fatty liver pregnancy, and lymphoma. *Abnormal LSM is defined based on LSM 
>10 kPa indicative of compensated advanced chronic liver disease (cACLD) (Baveno VI recommendations).
NRH 
(n=22) 
PVT 
(n=13) 
Miscellaneous 
(n=8) 
Total cohort  
(N=43) 
Demographics 
Age 61 ± 13 51 ± 12 53 ± 18 56 ± 14 
Male (%) 64 46 13 50 
Caucasian (%) 91 92 88 90 
BMI (kg/m2) 27 ± 4 30 ± 6 30 ± 6 28 ± 5 
Blood tests 
Total bilirubin (mg/dL) 1.3 ± 1.1 1.2 ± 0.8 2.4 ± 2.6 1.5 ± 1.5 
ALT (U/L) 41 ± 65 32 ± 36 26 ± 15 35 ± 50
Platelet count (k/mm3) 178 ± 146 167 ± 100 269 ± 158 193 ± 139 
INR 1.1 ± 0.2 1.4 ± 0.6 1.7 ± 1.2 1.4 ± 0.7
Varices (%) (n=34) 72 75 75 74
METAVIR Fibrosis Stage (n=38) 
None (%) 50 62 50 52 
F1 (%) 9 23 0 12
F2 (%) 27 0 38 21 
F3 (%) 0 0 13 2.4
F4 (%) 0 0 0 0 
Not available (%) 14 15 0 12 
Trans-jugular portal pressure measurements (n=33) 
RA (mmHg) 4 ± 3 5 ± 4 5 ± 3 5 ± 3 
FHVP (mmHg) 6 ± 2 9 ± 4 8 ± 4 7 ± 4
WHVP (mmHg) 13 ± 6 13 ± 5 19 ± 5 14 ± 6 
HVPG (mmHg) 7 ± 5 (n=15) 4 ± 2 (n=11) 11 ± 7 (n=7) 7 ± 5  
Transient elastography 
LSM (kPa) 11.0 ± 5.3 8.4 ± 5.4 26.7 ± 19.7 13.1 ± 11.5 
Minimum-Maximum (kPa) 4.4 - 22.0 3.6 – 18.8 7.4 – 67.8 3.6 – 67.8
LSM >6.5 kPa (%) 68 39 100 65 
*Abnormal LSM (%) 50 31 75 49 
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Figure Legend 
 
Figure 1. Flowchart of patients with NCPH in the study cohort. The ranges of LSM in each cohort and 
the proportion of patients with abnormal LSM are also mentioned.  “Miscellaneous” category included 
sarcoidosis, Budd-Chiari, acute fatty liver pregnancy, and lymphoma. Abbreviations:  LSM:  Liver Stiffness 
Measurement; cACLD: Compensated advanced chronic liver disease; NRH: Nodular Regenerative 
Hyperplasia; PVT: Portal Vein Thrombosis 
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